The role of the affective temperament in the treatment adherence in psychiatry
Lilia Bahrini, Rahma Damak, Mejda Cheour
The Pan African Medical Journal. 2016;25:2. doi:10.11604/pamj.2016.25.2.8400

Create an account  |  Sign in
EPI Helina 2017
"Better health through knowledge sharing and information dissemination "

Research

The role of the affective temperament in the treatment adherence in psychiatry

Cite this: The Pan African Medical Journal. 2016;25:2. doi:10.11604/pamj.2016.25.2.8400

Received: 10/11/2015 - Accepted: 19/06/2016 - Published: 02/09/2016

Key words: Adherence, MARS adherence, affective temperaments, temperament TEMPS

© Lilia Bahrini et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Available online at: http://www.panafrican-med-journal.com/content/article/25/2/full

Corresponding author: Lilia Bahrini, Psychiatry E Department, Razi Hospital, Cité les Oranger, 2010 Manouba, Medicine University of Tunis, Tunisia (lilia.bahrini@gmail.com)


The role of the affective temperament in the treatment adherence in psychiatry

Lilia Bahrini1,&, Rahma Damak1, Mejda Cheour1

 

1Psychiatry E Department, Razi Hospital, Cité les Oranger, 2010 Manouba, Medicine University of Tunis, Tunisia

 

 

&Corresponding author
Lilia Bahrini, Psychiatry E Department, Razi Hospital, Cité les Oranger, 2010 Manouba, Medicine University of Tunis, Tunisia

 

 

Abstract

Introduction: adherence to psychotropic medications is affected by factors related to the treatment, to the physician, to the environment and to the patient himself. The purpose of the present study was to investigate the influence of affective temperaments on treatment adherence.

 

Methods: thirty six stabilized outpatients were recruited from the aftercare consultation of Psychiatry to perform Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto questionnaire version (TEMPS-A) for affective temperaments and the Medication Adherence Rating Scale (MARS) for treatment adherence.

 

Results: the total MARS score was negatively correlated with the irritable temperament score. The MARS’s score relative to the attitude of patients to psychotropic medications and their negative side effects was negatively correlated with the cyclothymic, the irritable and anxious temperaments. Patients having a diagnosis of psychotic disorder had a significantly greater medication adherence and behaviour toward medication score compared to those having a diagnosis of affective disorder. A greater MARS’s score for the negative side effects and attitudes to psychotropic medication was associated with medication by neuroleptics with prolonged action.

 

Conclusion: the results of the present study suggest that patients with irritable temperament may have more difficult to follow psychotropic medications, and that patients with cyclothymic, irritable and anxious temperaments may be more attentive and sensitive toward psychotropic medications and their negative side effects.

 

 

Introduction    Down

Treatment adherence is one of the most important prognostic factors for mental illness. Haynes defines adherence as the "match between the patient's behaviour and his doctor's recommendations for a program therapy (medication, psychotherapy, hygiene of life, additional tests or presence to appointments)" [1]. The World Health Organization defines adherence as «the extent to which a person’ s behaviour-taking medication, following a diet, or making healthy lifestyle changes-corresponds with agreed-upon recommendations from a health-care provider » [2]. In general, across all medical specialties, it is estimated that 25% of inpatients and 50% of outpatients don’t take medication correctly [1, 3]. The poor adherence to treatment in psychiatry is frequent. It affects 15 to 25% of inpatients and 50% of outpatients. Twenty per cent of patients in psychiatry does not buy their drugs in the months following the prescription and 30 to 50% of medicines purchased would be not consumed [4]. In psychiatry, treatment adherence is of extreme importance, because the consequences of poor compliance are major. The consequences in terms of efficacy and safety must be firstly considered. The economic consequences of the poor compliance must also be taken into account. They are expressed in terms of direct and indirect costs associated with relapses, rehospitalisation, chronicity, or down productivity [5-11]. The determinants of adherence can be divided into four factors: factors related to treatment [9], factors related to the physician and physician-patient relationship [3, 12], factors related to the environment [9] and factors related to the patient himself. The first three factors are dynamic and it is here that most of the studies have been done [10]. The factors related to the patient are in their majority static, and an action at this level is often the most difficult. Patient’s characteristics taken into play in respect of adherence are multiple; they are both cognitive, behavioural, emotional and psychopathological. To these are added the notions of knowledge and beliefs [13-15]. Thus, many studies have highlighted that poor compliance is favoured by extreme ages, male gender, low socioeconomic level, low cultural level and psychosocial isolation and certain personalities like hypochondriac or paranoid. Meanwhile, the temperament has been little studied as a factor related to the patient and being decisive in adherence [16]. Temperaments are imperturbable variations of personality, traits and ways of reacting to the environment that characterize individuals and remain constant throughout several different situations [17]. The purpose of this study was to highlight the role of patient's affective temperament in adherence to treatment in psychiatry.

 

 

Methods Up    Down

Participants

 

This was cross-sectional study. Thirty-six stabilized outpatients were recruited from the aftercare consultation of Psychiatry E department of the Razi Hospital in Tunis, over a period of three months from January to March 2015. All patients meeting the following criteria were included: literate patients and stabilized patients on treatment for more than 3 months. Were excluded all patients with a psychiatric examination showing symptoms of relapse. According to Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (Text Revision) (DSM-IV-TR), psychiatric diagnoses were schizophrenia (n=19), bipolar disorders (n=11), schizoaffective disorder (n=3) and major depressive disorder (n=3). Each participant gave his oral consent to participate in this study. The research ethic board of Razi hospital approved the study.

 

Temperament assessment

 

The temperament was assessed using the « Temperament Evaluation of Memphis, Paris and San Diego- Auto-questionnaire » version (TEMPS-A). The TEMPS-A is based on interview versions of the depressive, cyclothymic, irritable and hyperthymic temperaments [18-22] which have been validated in an Italian population of 1010 students aged from 14 to 25 [23, 24]. The Italian study upheld the four-factor structure of « Temperament Evaluation of Memphis and Paris Interview or Italian version (TEMP-I). The present self-rated (auto questionnaire) version of TEMPS-A [25] has been enriched with the addition of an anxious temperament [26]. The TEMPS-A was translated in more than 32 languages and is used worldwide. The validated Arabic version of TEMPS-A questionnaire was used [27, 28] and proved to be suitable to the Tunisian population [29].

 

Adherence measurement

 

The adherence was assessed using the « Medication Adherence Rating Scale » (MARS). MARS was created by Thompson and al. [30] for the assessment of adherence in psychiatric patients. They identified several deficiencies in the « Drug Attitude Inventory » (DAI) as a measure of adherence and proposed a new inventory, the MARS scale, that incorporates features of both the DAI [31, 32] and the « Medication Adherence Questionnaire » (MAQ) [33] but which they claimed to have greater validity and clinical utility. The scale includes 10 items and was first validated in patients with schizophrenia. MARS examines adherence behaviours and attitudes toward medication with relatively simplistic scoring [30]. MARS is useful in psychiatric practices or psychiatric clinic settings [30]. The MARS includes 10 yes or no items. It explores 3 factors, factor 1 is relative to the four first items that explore "the medication adherence and behaviour", factor 2 is relative to the items 5-8 that explore ‘the attitude to taking medication’ and ‘the beliefs about medications’ and factor 3 is relative to items 9 and 10 that explore "the negative side-effects and attitudes to psychotropic medication". The patient should be asked to respond to the statements in the questionnaire by circling the answer which best describes their behaviour or attitude towards their medication during the past week. Responses for a good adherence are "no" for the items 1-6 and 9-10 and "yes" to the items 7-8. [34-36]. Scores =5 were considered as high which mean that treatment adherence was sufficiently good and scores < 5 were considered as low which mean that treatment adherence was bad. In this study, we used the Arab version validated in Tunisian dialect. This validation was made in the context of a doctoral thesis in medicine at the Tunis Faculty of Medicine and is actually the subject of a paper being submitted.

 

Statistical analysis

 

Data for all cases were compiled electronically and analysed using SPSS version 18. The Kolmogorov-Smirnov test was used to test the normal distribution of the data. T-test and Chi-square were respectively used for comparison of continuous or parametric variables (Mann–Whitney and Fisher exact test when appropriated). Pearson's correlation coefficients were obtained between the age, age of onset, duration of illness, number of medication, total score of MARS, MARS’s factor 1, 2 and 3 scores and temperament scores. We referred to levels of significance of p<0.05.

 

 

Results Up    Down

Descriptive study

 

Socio-demographic features: the population mean age was 37 years ± 8.21 (men= 66.7% and women= 33.3%). Twenty six patients (72.2%) were single, eight of them (22.2%) were married and two patients (5.6%) were divorced. More than the half of our population (58.3%) reached the secondary education level, 27.8% the primary level and 13.9% the high school level. The family support was good in 63.9% of cases and bad in 33.3% of cases.

 

Clinical features: sixty-one point one percent of the patients had psychotic disorders and 38.9% had affective disorders. The mean age of onset was 25.47 years ± 6.05 and the mean duration of illness was 11 years ± 8.76. Twenty three patients (63.9%) were current smoker, eleven of them (30.6%) had history of recent alcohol consumption and two had history of recent cannabis abuse. The mean number of re-hospitalizations was 3.58 ± 2.06 with a range of 1-9. Prescription rate varied between different types of psychotropic medications. The mean number of medication was 2.56 ± 0.87 with a range of 1 to 4. The Figure 1 shows the rates of the different prescribed neuroleptics. Mood stabilisers were prescribed for 44.4% of the patients.

 

TEMPS-A assessment: according to the TEMPS-A, anxious temperament was the more frequent temperament with a mean score of 12. 32 ± 6.25, flowed by the hyperthymic temperament (mean score 11.3±3.97), cyclothymic temperament (mean score: 11.22±5.13) and depressive temperament (mean score 11±4.09). The mean score of the irritable temperament was 7.19 ± 4.62. MARS measurement: the majority of patients; 77.8% (n=28) had a high MARS score and only 22.2% (n=8) had a low MARS score. As shown in Table 1, the mean score of the total MARS was 6.28 ± 2.37, which mean that treatment adherence was sufficiently good.

 

Association between MARS scores and TEMPS-A

 

The results of this study showed a negative correlation between the total MARS score and the irritable temperament score (p=0.026, r= -0.37) but no correlations with the other temperaments scores. As shown in Table 2, the mean MARS’s factor 3 score was negatively correlated with cyclothymic (p=0.004; r=-0.46), irritable (p=0.004; r=-0.46) and anxious temperaments (p=0.04; r=--0.37). As shown in Table 3, the depressive and irritable temperaments were significantly associated with low MARS (p=0.022; p= 0.009).

 

Association between MARS scores and socio-demographic and clinic features

 

The results of this study did not show any association between socio-demographic features and the mean scores of MARS, MARS’s factor 1and 3 and the high score of MARS. The attitude to taking medication and the beliefs about medication score was significantly associated with the marital status with greater score among the married patients compared to the single and divorced ones (p=0.049). Concerning the clinical features, patients having a diagnosis of psychotic disorder had a significantly greater medication adherence and behaviour toward medication score compared to those having a diagnosis of affective disorder (2.95 ±1.32 vs 1.93 ± 1.14; p=0.023). The number of patients having a high score of MARS were significantly higher among those having a diagnosis of psychotic disorders (p=0.018). A greater score for the negative side effects and attitudes to psychotropic medication was associated with medication by neuroleptics with prolonged action (p=0.004). The patients having a high score of MARS were significantly associated with a higher mean number of re-hospitalizations (3.93 vs 2.38; p=0.05).

 

 

Discussion Up    Down

In our study, although the majority of patients had high MARS scores (77.8% having scores > 5) the mean MARS score remains low (6.28/10) indicating that patients did not have a sufficiently good adherence. Furthermore, the mean MARS’s factor 1 score was 2.56/4. This indicates that the patients’ adherence behaviour was not sufficiently good toward their medication, with frequent behaviours such as omission, oversight or discontinuation of treatment. This result is consistent with the data of literature showing that poor adherence to treatment in psychiatry is frequent [4]. The adherence to treatment remains difficult to estimate [37-39]. Several evaluation methods were proposed, they are divided into direct and indirect measurements. Direct measurements, which include measures such as detection of the drug in biological fluid [40] and direct observation of the patient taking medications, are objective methods. More commonly used are the indirect measurements including medication Event Monitoring System (pill counts) [10], self-report measures, prescription claims data and the use of adherence scales [9]. Although several studies demonstrated the superiority of the direct measures in the evaluation of the adherence to treatment, we opted in this study, for an indirect measure by using the auto-questionnaire of MARS. Although the MARS scale is subjective, it is specific to the psychiatric population. Furthermore, we have a validated version in Arabic adapted to the Tunisian dialect. The results of our study show that when taking into consideration the total score of MARS, the treatment adherence was good in 77.8% of patients. However, by considering each factor separately, the results show that the patients had a passable attitude toward taking medication and that the subjective perceptions on drugs and their negative side-effects was not good enough. Hogan and al [32] believe that the adherence to treatment is strongly linked to the unconscious effect of an aversive interoceptive conditioning. A negative perception could influence the future behaviour of the subject without his knowledge. They emphasize the subjective experience to the detriment of the only adverse effects. The way in which the patient feels his treatment, the beliefs or knowledge on the beneficial aspects, the undesirable effects and the action of the drugs influence less significantly the adherence to treatment.

 

Association between adherence to treatment and the affective temperament

 

The results of this study showed that the depressive and irritable temperament was significantly correlated with a poor adherence to treatment. These results are consistent with those found in the study of Kamei and al [16] who assessed the adherence using the« Visual Analogue Scales » (VAS) and the « Drug Attitude Inventry-10 » (DAI-10). In fact, their results showed that VAS scores for total compliance were significantly and negatively associated with depressive temperament scores while VAS scores for compliance with dose were significantly and negatively associated with depressive temperament scores and irritable temperament scores. They also found that the VAS scores for compliance with dose and DAI-10scores were significantly and positively associated with hyperthymic temperament scores indicating that hyperthymic patients had a better adherence to treatment. In our study, the hyperthymic temperament wan not associated to a better adherence. This difference with the results of the study of Kamei and al [16], may be explained by the different tools of adherence assessment. MARS, VAS and DAI-10 can measure different aspects of adherence leading to no significant association. In our study, the cyclothymic, irritable or anxious temperaments were significantly associated with a bad « attitude to psychotropic medication and their negative side-effects scores ».

 

Association between adherence to treatment and socio-demographic and clinical features

 

Concerning the socio-demographic features, our study has shown that married patients had a better attitude toward drugs. Kampman and al [41] showed in their study that being single is a risk factor for a poor adherence. More than being single, the fact of living alone increases the bad adherence behaviour [41-44]. The association between marital status and treatment adherence could be explained by the fact that married patients are supervised and assisted by their spouses in their daily lives. Moreover, in our study the family support has not been associated with a better adherence to treatment. Thus, the spouses seem to be better guarantors for the drug therapy than the rest of the family. Parents are often older and siblings are engaged in their own family and professional life. Our study has not found significant association between the adherence to treatment and the addictive behaviours such as smoking, alcoholism or substance use. This is inconsistent with the data from the literature [9]. Concerning the clinical features, our study has shown that patients with psychotic disorders had a better adherence and a better adherence behaviour toward medication than those with affective disorders. At first sight, this result might seem paradoxical. However, several studies have demonstrated that although the insight during the relapses is low both in schizophrenic and bipolar patients [45, 46], and that it is best among the bipolar during intervals of stabilization, the differences between the two groups are in the dimensions of the insight [47]. Indeed, after treatment the bipolar patients improve their insight of illness and of illness’s symptoms while schizophrenics improve their insight of the necessity of treatment while the insight of illness remain poor [47]. This improvement of the insight of the necessity of treatment may be explained by the fact that the schizophrenic patients have essentially positive psychotic symptoms which are known to be predictive of the improvement of insight [48]. The results of the current study showed that the score of the patient’s attitude toward psychotropic medication and their negative side effects was greater among patients treated by prolonged neuroleptic action. In fact, Samalin and al [49] found that this form of neuroleptic is still poorly used in routine. It should not be only reserved to noncompliant patients but even to those having a sufficiently good adherence to treatment to ensure the persistence of this good attitude toward medication. Patients having a higher number of hospitalizations had a higher MARS scores. This result was expected. Poor compliance is often related with a higher number of hospitalization [47].

 

 

Conclusion Up    Down

The main results of this study suggest that patients with depressive and irritable temperaments had a poor adherence to treatment. These patients require more education concerning the necessity of medication. Moreover, patients with cyclothymic, irritable and anxious temperaments are more sensitive toward the negative side effects of psychotropic medication and require more assistance and advices concerning psychotropic medication. Therefore, consideration of patients’ temperament could be improved the education which will be more targeted.

What is known about this topic

  • The non-treatment adherence is one of the main reasons for relapse of psychiatric patients;
  • The determinants of treatment adherence are related to the treatment, the environment, the therapeutic alliance and certain factors related to the patient himself;
  • Affective temperament plays an important role and influences human behavior.

What this study adds

  • The present study showed the influence of affective temperament on the quality of patient compliance in psychiatry;
  • In the present study, depressive and irritable temperaments were associated with a poor therapeutic compliance.

 

 

Competing interests Up    Down

The authors declare no competing interest.

 

 

Authors’ contributions Up    Down

All authors have read and agreed to the final version of this manuscript and have equally contributed to its content and to the management of the case.

 

 

Tables and figure Up    Down

Table 1: mean scores of Medication Adherence Rating Scale (MARS)

Table 2: correlations between Medication Adherence Rating Scale (MARS) and TEMPS-A scores

Table 3: associations between TEMPS-A scores and high/low MARS (Medication Adherence Rating Scale ) score

Figure 1: distribution of patients by type of prescribed neuroleptic

 

 

References Up    Down

  1. Haynes RB, Sackett DL. Compliance with therapeutic regimens. Johns Hopkins University Press. 1976. Google Scholar

  2. Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization. 2003. Google Scholar

  3. Corruble E, Hardy P. Observance du traitement en psychiatrie. Encyclopédie médicochirurgicale. 2003. Google Scholar

  4. Blondiaux I, Alagille M, Ginestet D. Adhésion aux traitements biologiques en psychiatrie. Encycl Méd Chir. 1994; 1-3. Google Scholar

  5. Donovan JL. Patient decision making: the missing ingredient in compliance research. International journal of technology assessment in health care. 1995; 11(3): 443-55. PubMed | Google Scholar

  6. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making?. Social science & medicine. 1992; 34(5): 507-13. PubMed | Google Scholar

  7. Home R. Representations of medication and treatment: advances in theory and measurement. Harwood Academic London. 1997. Google Scholar

  8. Melnikow J, Kiefe C. Patient compliance and medical research. Journal of general internal medicine. 1994; 9(2): 96-105. PubMed | Google Scholar

  9. Misdrahi D, Llorca P, Lancon C, Bayle F. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. L'Encephale. 2001; 28(3 Pt 1): 266-72. PubMed | Google Scholar

  10. Morris LS, Schulz R. Patient compliance-an overview. J Clin Pharm Ther. 1992 Oct; 17(5): 283-95. PubMed | Google Scholar

  11. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996 Mar; 17 Suppl A: 8-15. PubMed | Google Scholar

  12. Frank E, Kupfer DJ, Siegel LR. Alliance not compliance: a philosophy of outpatient care. Journal of Clinical Psychiatry. 1995. Google Scholar

  13. Donohoe G, Owens N, O’donnell C, Burke T, Moore L, Tobin A et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. European Psychiatry. 2001; 16(5): 293-8. PubMed | Google Scholar

  14. Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry. 2004; 37(3): 103-9.. PubMed | Google Scholar

  15. Ruscher S, deWit R, Mazmanian D, editors. Psychiatric patients attitudes about medication and factors affecting non-adherence. International Journal Of Psychology; 1996: Psychology Press 27 Church Rd, Hove, East Sussex, England BN3 2FA. Google Scholar

  16. Kamei K, Terao T, Katayama Y, Hoaki N. Affective temperaments and psychotropic adherence. Journal of affective disorders. 2013; 150(3): 1142-7. PubMed | Google Scholar

  17. Gonda X, Vázquez GH. Theoretical and clinical overview of affective temperaments in mood disorders. Psicodebate. 2014; 14(2):39-58. Google Scholar

  18. Akiskal H. Delineating irritable-choleric and hyperthymic temperaments as variants of cyclothymia. J Pers Disord. 1992; 6: 326-42. Google Scholar

  19. Akiskal H, Khani M, Scott-Strauss A. Cyclothymic temperamental disorders. Psychiatr Clin North Am. 1979; 2(3): 527-54. PubMed | Google Scholar

  20. Akiskal H, Mallya G. Criteria for the" soft" bipolar spectrum: treatment implications. Psychopharmacol Bull. 1987; 23(1): 68-73. PubMed | Google Scholar

  21. Akiskal HS, Akiskal K. Cyclothymic, hyperthymic and depressive temperaments as subaffective variants of mood disorders. In: Tasman A, Riba MB, editors. Annual review of psychiatry. Vol. 11. Washington: American Psychiatric Press; 1992. pp. 43–62. Google Scholar

  22. Akiskal HS, Djenderedjian AH, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry. 1977; 134(11): 1227-33. PubMed | Google Scholar

  23. Akiskal H, Placidi G, Maremmani I, Signoretta S, Liguori A, Gervasi R et al. TEMPS-I: delineating the most discriminant traits of the cyclothymic, depressive, hyperthymic and irritable temperaments in a nonpatient population. Journal of affective disorders. 1998; 51(1): 7-19. PubMed | Google Scholar

  24. Placidi G, Signoretta S, Liguori A, Gervasi R, Maremmani I, Akiskal H. The semi-structured affective temperament interview (TEMPS-I): reliability and psychometric properties in 1010 14-26-year-old students. Journal of affective disorders. 1998; 47(1): 1-10. PubMed | Google Scholar

  25. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. Journal of affective disorders. 2005; 85(1): 3-16. PubMed | Google Scholar

  26. Akiskal H. Toward a definition of generalized anxiety disorder as an anxious temperament type. Acta Psychiatrica Scandinavica. 1998; 98(s393): 66-73.. PubMed | Google Scholar

  27. Karam EG, Mneimneh ZN, Salamoun MM, Akiskal HS, Akiskal KK. Suitability of the TEMPS-A for population-based studies: ease of administration and stability of affective temperaments in its Lebanese version. Journal of affective disorders. 2007; 98(1): 45-53. PubMed | Google Scholar

  28. Vázquez GH, Tondo L, Mazzarini L, Gonda X. Affective temperaments in general population: a review and combined analysis from national studies. Journal of affective disorders. 2012; 139(1): 18-22. PubMed | Google Scholar

  29. Masmoudi J, Trabelsi S, Charfeddine F, Ben AB, Guermazi M, Jaoua A et al. Evaluation of affective temperaments in the postpartum depressive symptomatology. Encephale. 2010 Jun; 36 Suppl 2: D14-21. PubMed | Google Scholar

  30. Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia research. 2000; 42(3): 241-7. PubMed | Google Scholar

  31. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin. 1993; 19(3): 609. PubMed | Google Scholar

  32. Hogan TP, Awad A, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological medicine. 1983; 13(1): 177-83. PubMed | Google Scholar

  33. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986; 24(1): 67-74. PubMed | Google Scholar

  34. Charpentier A, Goudemand M, Thomas P. Therapeutic alliance, a stake in schizophrenia. L'Encephale. 2009; 35(1): 80-9. PubMed | Google Scholar

  35. Misdrahi D, Verdoux H, Llorca P, Baylé F. Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of Medication Adherence Rating Scale (MARS). L'Encéphale. 2004; 30(4): 409. PubMed | Google Scholar

  36. Urquhart J. The electronic medication event monitor. Clinical pharmacokinetics. 1997; 32(5): 345-56. PubMed | Google Scholar

  37. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry. 1983 Jun; 44(6 Pt 2): 3-6. PubMed | Google Scholar

  38. Urquhart J. Role of patient compliance in clinical pharmacokinetics. Clinical pharmacokinetics. 1994; 27(3): 202-15. PubMed | Google Scholar

  39. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Controlled clinical trials. 2000; 21(5): S188-S94. PubMed | Google Scholar

  40. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: Principles and practice. Psychiatr Clin North Am. 1993 Sep; 16(3): 611-45. PubMed | Google Scholar

  41. Kampman O, Laippala P, Väänänen J, Koivisto E, Kiviniemi P, Kilkku N et al. Indicators of medication compliance in first-episode psychosis. Psychiatry research. 2002; 110(1): 39-48. PubMed | Google Scholar

  42. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological medicine. 1992; 22(03): 787-97. PubMed | Google Scholar

  43. Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: the influence of clinical variables, relatives' knowledge and expressed emotion. Psychological medicine. 2003; 33(1): 91-6. PubMed | Google Scholar

  44. Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry. 1974; 31(1): 67-72. PubMed | Google Scholar

  45. Schuepbach D, Goetz I, Boeker H, Hell D. Voluntary vs involuntary hospital admission in acute mania of bipolar disorder: results from the Swiss sample of the EMBLEM study. Journal of affective disorders. 2006; 90(1): 57-61. PubMed | Google Scholar

  46. Sturman ED, Sproule BA. Toward the development of a mood disorders insight scale: modification of Birchwood’s psychosis insight scale. Journal of affective disorders. 2003; 77(1): 21-30. PubMed | Google Scholar

  47. Otheman Y, Doufiq J, Kasouati J, Yahia A, Mehssani J, Ouanass A et al, editors. Comparative study of insight and factors influencing it in schizophrenia and bipolar disorder in a population of Moroccan hospitalized patients. Annales Medico-Psychologiques; 2014: Masson Editeur 21 Street Camille Desmoulins, Issy, 92789 Moulineaux Cedex 9, France. Google Scholar

  48. Weiler MA, Fleisher MH, McArthur-Campbell D. Insight and symptom change in schizophrenia and other disorders. Schizophrenia Research. 2000; 45(1): 29-36. PubMed | Google Scholar

  49. Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca P. French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics. Encephale. 2013 Dec; 39 Suppl 4: 189-203. PubMed | Google Scholar

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


The Pan African Medical Journal articles are archived on Pubmed Central. Access PAMJ archives on PMC here

Volume 26 (Jan - Apr 2017)

Article tools

PDF in process
Log in to comment
Contact the corresponding author
Download to Citation Manager
EndNote
Reference Manager
Zotero
BibTex
ProCite


This article authors

On Pubmed
On Google Scholar

Rate this article

Altmetric

PAMJ is a member of the Committee on Publication Ethics

PAMJ is published in collaboration with the African Field Epidemiology Network (AFENET)
Currently tracked by: DOAJ, AIM, Google Scholar, AJOL, EBSCO, Scopus, Embase, IC, HINARI, Global Health, PubMed Central, PubMed/Medline, Ulrichsweb, More to come . Member of COPE.

ISSN: 1937-8688. © 2017 - Pan African Medical Journal. All rights reserved